<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110032</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02651</org_study_id>
    <secondary_id>UPCC 01304</secondary_id>
    <secondary_id>CDR0000423313</secondary_id>
    <nct_id>NCT00110032</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors</brief_title>
  <official_title>Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects of fluorine F18 EF5 when given during&#xD;
      positron emission tomography to find oxygen in tumor cells of patients who are undergoing&#xD;
      surgery or biopsy for newly diagnosed brain tumors. Diagnostic procedures using fluorine F 18&#xD;
      EF5 and positron emission tomography to detect tumor hypoxia may help in planning cancer&#xD;
      treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety of fluorine F 18 EF5 (^18F-EF5) in patients with newly diagnosed&#xD;
      brain tumors undergoing surgery or biopsy.&#xD;
&#xD;
      Secondary I. Determine the pharmacokinetics and biodistribution of ^18F-EF5 administered&#xD;
      before and after nonradioactive EF5 in these patients.&#xD;
&#xD;
      II. Determine the ability of positron emission tomography (PET) scanning using ^18F-EF5 to&#xD;
      detect tumor hypoxia in these patients.&#xD;
&#xD;
      III. Determine the presence and pattern of nonradioactive EF5 binding by immunohistochemistry&#xD;
      (IHC) and/or flow cytometry in these patients.&#xD;
&#xD;
      IV. Correlate tumor hypoxia, as measured by PET scanning using ^18F-EF5, with EF5 staining by&#xD;
      IHC and/or flow cytometry and recurrence-free survival of these patients.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 3 groups.&#xD;
&#xD;
      Group 1: Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole&#xD;
      body positron emission tomography (PET) scanning OR whole body PET scanning only. Patients&#xD;
      then receive nonradioactive EF5 IV over 1-2 ½ hours.&#xD;
&#xD;
      Group 2: Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV.&#xD;
      Patients then undergo whole brain and whole body PET scanning.&#xD;
&#xD;
      Group 3: Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then&#xD;
      undergo whole brain PET scanning. Approximately one day after EF5 administration, all&#xD;
      patients undergo surgery or biopsy of the tumor AND biopsy of normal skin adjacent to the&#xD;
      incision.&#xD;
&#xD;
      Patients are followed at 2-4 weeks and 4-6 weeks after EF5 administration and then every 3&#xD;
      months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>June 2005</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of F-18-EF5 based on the NCI CTCAE version 3.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Summarized in descriptive statistics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of radioactively labeled [F-18]-EF5</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of hypoxia, determined by [F-18]-EF5 PET imaging</measure>
    <time_frame>Up to day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IHC analysis of cold EF5</measure>
    <time_frame>Up to day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Ependymoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Brain Stem Glioma</condition>
  <condition>Adult Central Nervous System Germ Cell Tumor</condition>
  <condition>Adult Choroid Plexus Tumor</condition>
  <condition>Adult Craniopharyngioma</condition>
  <condition>Adult Diffuse Astrocytoma</condition>
  <condition>Adult Ependymoblastoma</condition>
  <condition>Adult Ependymoma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Grade I Meningioma</condition>
  <condition>Adult Grade II Meningioma</condition>
  <condition>Adult Grade III Meningioma</condition>
  <condition>Adult Medulloblastoma</condition>
  <condition>Adult Meningeal Hemangiopericytoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Adult Myxopapillary Ependymoma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Adult Pilocytic Astrocytoma</condition>
  <condition>Adult Pineoblastoma</condition>
  <condition>Adult Pineocytoma</condition>
  <condition>Adult Subependymoma</condition>
  <condition>Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)</condition>
  <condition>Meningeal Melanocytoma</condition>
  <arm_group>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EF5</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <other_name>surgery, conventional</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo PET</description>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fluorine F 18 EF5</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <other_name>18F-EF5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group 1 (fluorine F 18 EF5, PET)</arm_group_label>
    <arm_group_label>Group 2 (EF5, PET)</arm_group_label>
    <arm_group_label>Group 3 (EF5, PET)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed and/or clinical and imaging evidence of a de novo mass that&#xD;
             is likely to be a brain tumor&#xD;
&#xD;
          -  Amenable to debulking surgery or surgical resection or biopsy as standard initial&#xD;
             therapy for the tumor&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
          -  WBC count ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin &lt; 1.2 mg/dL&#xD;
&#xD;
          -  Creatinine &lt; 1.3 mg/dL&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No other significant cardiac condition that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
             participation&#xD;
&#xD;
          -  Weight ≤ 130 kg&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 3&#xD;
&#xD;
          -  No history of allergic reaction attributed to metronidazole&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Michael Hahn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Choroid Plexus Neoplasms</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
    <mesh_term>Hemangiopericytoma</mesh_term>
    <mesh_term>Glioma, Subependymal</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

